Medication info
Sitabiang Duo Tablet 50/500 mg

Sitabiang Duo Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300759 · Approved 2023.03.06 · Insurance code 645605860

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2. Contraindications in Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar in patients with type 2 diabetes by using sitagliptin and metformin together. It assists patients who are combining dietary and exercise therapies to manage their blood sugar more effectively. This helps stabilize blood sugar levels and prevent complications related to diabetes. If used safely, it can be very helpful in blood sugar control.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2. Contraindications in Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication contains sitagliptin and metformin and is used for the treatment of diabetes. First, a serious allergic reaction may occur during the use of this medication, so if you experience symptoms such as skin rash, difficulty breathing, or swelling of the face or neck, you should immediately stop taking the medication and consult your doctor. Additionally, this medication may cause inflammation of the pancreas known as pancreatitis, so if you experience abdominal pain, nausea, vomiting, or severe abdominal discomfort, you should quickly visit a hospital. The metformin component can rarely cause a serious metabolic disorder known as lactic acidosis, accompanied by symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, and loss of appetite, so if these symptoms appear, you should immediately stop taking the medication and inform a healthcare professional. This medication should not be administered to patients with moderate to severe renal impairment, patients with acute heart failure or serious infections, and women who are pregnant or breastfeeding. Additionally, this medication must be temporarily halted before and after undergoing tests that use iodinated contrast agents, and it should be resumed only after renal function has been confirmed to be normal. When taking this medication, there is a risk of hypoglycemia when used with other potent blood sugar-lowering medications, so blood sugar levels should be checked regularly and the dosage adjusted according to the physician's instructions as needed. Elderly patients or those with weakened renal function should have regular kidney function tests and consult a doctor immediately if any abnormal signs occur. Moreover, this medication contains specific coloring agents, so patients allergic to those components should exercise caution. If food intake is restricted prior to surgery, the medication should be discontinued 48 hours beforehand, and it should only be resumed after confirming normal kidney function post-surgery. Finally, it is advisable to avoid alcohol intake while on this medication, and regular meals, exercise, along with periodic blood sugar and kidney function tests are important.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe joint pain accompanied by disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, dyspnea, unstable angina, dizziness, decreased appetite, dermatitis, appetite loss, weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and the storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius. Storing it this way helps preserve the medication's effectiveness for a longer time.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.